Chronic lymphocytic leukaemia: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 200+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Trials whose registry record says individual participant data (IPD) will be shared.

• A Phase 1 Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies

  2026-525234-39-00· Janssen Cilag International· Source

• A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).

  NCT05947851· Merck Sharp & Dohme LLC· Source

• Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

  NCT04269902· National Cancer Institute (NCI)· Source

• A Rollover Study of CC-122

  NCT05688475· Bristol-Myers Squibb· Source

• A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring

  NCT06788509· Janssen Research & Development, LLC· Source

• A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

  NCT06588478· Loxo Oncology, Inc.· Source

• PICAROS - Acalabrutinib RWE on 1L CLL in Spain

  NCT05999877· AstraZeneca· Source

• A Clinical Trial of MK-1045 in People With B-cell Cancer (MK-1045-006)

  NCT07709000· Merck Sharp & Dohme LLC· Source

• A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

  NCT07218341· Eli Lilly and Company· Source

• A Long-term Extension Study of PCI-32765 (Ibrutinib)

  NCT01804686· Janssen Research & Development, LLC· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 6
• Mendelian Randomization Analysis 2
• CRISPR-Cas Systems 1
• Gene Expression Profiling 9
• Sequence Analysis, RNA 1
• Whole Genome Sequencing 1
• Exome Sequencing 1
• Proteomics 2
• Metabolomics 1
• Mass Spectrometry 2
• Flow Cytometry 20
• Immunohistochemistry 6
• Circulating Tumor DNA 1
• Xenograft Model Antitumor Assays 9
• Magnetic Resonance Imaging 3
• Machine Learning 9
• Cohort Studies 18
• Genome-Wide Association Study 2

See which targets of this disease your abstract mentions, and go to the people working on them.